Fujimoto Pharmaceutical Corp.
http://www.fujimoto-pharm.co.jp/jp/eng/eng2.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fujimoto Pharmaceutical Corp.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
SymBio shifts bendamustine's multiple myeloma focus to second-line use
SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.
Torisel among new approval recommendations in Japan
Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC).
Japan listing includes thalidomide for myeloma
Japan's Central Social Insurance Medical Council (Chuikyo) has granted reimbursement prices to a group of drugs including Fujimoto Pharmaceutical's thalidomide product Thaled for the orphan indication of refractory multiple myeloma.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice